Search Results
Search for other papers by Mohid S Khan in
Google Scholar
PubMed
Search for other papers by Martyn E Caplin in
Google Scholar
PubMed
as a curative approach. Often neuroendocrine tumours (NETs) have metastases present at the time of diagnosis; therefore, curative resection is usually not possible, and when surgery is undertaken, it can be considered palliative in view of residual
Search for other papers by Christodoulos P Pipinikas in
Google Scholar
PubMed
Search for other papers by Alison M Berner in
Google Scholar
PubMed
Search for other papers by Teresa Sposito in
Google Scholar
PubMed
Neuroendocrine Tumour Unit and Department of Oncology, Royal Free Hospital, London, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
), most commonly liver metastases, 5-year survival is 16–46% ( Mignon et al. 2000 , Viúdez et al. 2016 , Batukbhai et al. 2019 ) ( Fig. 1A ). Figure 1 Overview of the multi-layered pancreatic neuroendocrine tumours (PanNET) complexity. (A
Search for other papers by Anela Blažević in
Google Scholar
PubMed
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Gaston J H Franssen in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Marie-Louise F van Velthuysen in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Introduction Small intestinal neuroendocrine tumours (SI-NETs) are rare neoplasms with an incidence of approximately 0.2–1.2 per 100,000 individuals. However, due to the mostly indolent nature and increasing incidence, their prevalence is
Search for other papers by C Bouvier in
Google Scholar
PubMed
Nurse developments in the management of neuroendocrine tumours have changed significantly over the past three years. At the Royal Free Hospital we set up the nurse specialist role due to the expansion of patients being referred to the specialist unit, and the obvious need for a nursing input into their care. The nurse specialist can make a significant contribution within the context of a multidisciplinary team especially in the production of guidelines and policies to ensure and maintain high standards of practice, education for the patient, and the provision of expertise and security that the patient requires when diagnosed with a rare disease.
Search for other papers by R Srirajaskanthan in
Google Scholar
PubMed
Search for other papers by G Dancey in
Google Scholar
PubMed
Search for other papers by A Hackshaw in
Google Scholar
PubMed
Search for other papers by T Luong in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by T Meyer in
Google Scholar
PubMed
). Neuroendocrine tumours (NETs) are uncommon tumours that can occur in almost any organ and are thought to originate from neuroendocrine cells ( Caplin et al . 1998 , Modlin et al . 2008 ). The most common sites of origin is from gastroenteropancreatic tract
Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Institute for Liver and Digestive Disease, Royal Free Hospital, University College London, London, UK
Search for other papers by Luohai Chen in
Google Scholar
PubMed
Search for other papers by Gopinath Gnanasegaran in
Google Scholar
PubMed
Search for other papers by Dalvinder Mandair in
Google Scholar
PubMed
Search for other papers by Christos Toumpanakis in
Google Scholar
PubMed
Search for other papers by Martyn Caplin in
Google Scholar
PubMed
Search for other papers by Shaunak Navalkissoor in
Google Scholar
PubMed
Introduction 177 Lutetium-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-Dotatate) is a peptide receptor radionuclide therapy (PRRT) licensed for treatment in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours (NET
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by D Mandair in
Google Scholar
PubMed
Search for other papers by C Vesely in
Google Scholar
PubMed
Search for other papers by L Ensell in
Google Scholar
PubMed
Search for other papers by H Lowe in
Google Scholar
PubMed
Search for other papers by V Spanswick in
Google Scholar
PubMed
Search for other papers by J A Hartley in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK
Search for other papers by T Meyer in
Google Scholar
PubMed
limited by low rates of detection and isolation. CTCs have been identified in patients with metastatic neuroendocrine tumours (NETs) using the FDA-cleared CellSearch (Janssen Diagnostics) technology, a semi-automated platform that uses immunomagnetic
Search for other papers by M T Barakat in
Google Scholar
PubMed
Search for other papers by K Meeran in
Google Scholar
PubMed
Search for other papers by S R Bloom in
Google Scholar
PubMed
Neuroendocrine tumours are a heterogeneous group including, for example, carcinoid, gastroenteropancreatic neuroendocrine tumours, pituitary tumours, medullary carcinoma of the thyroid and phaeochromocytomas. They have attracted much attention in recent years, both because they are relatively easy to palliate and because they have indicated the chronic effect of the particular hormone elevated. As neuroendocrine phenotypes became better understood, the definition of neuroendocrine cells changed and is now accepted as referring to cells with neurotransmitter, neuromodulator or neuropeptide hormone production, dense-core secretory granules, and the absence of axons and synapses. Neuroendocrine markers, particularly chromogranin A, are invaluable diagnostically. Study of several neuroendocrine tumours has revealed a genetic etiology, and techniques such as genetic screening have allowed risk stratification and prevention of morbidity in patients carrying the particular mutation. Pharmacological therapy for these often slow-growing tumours, e.g. with somatostatin analogues, has dramatically improved symptom control, and radiolabelled somatostatin analogues offer targeted therapy for metastatic or inoperable disease. In this review, the diagnosis and management of patients with carcinoid, gut neuroendocrine tumours, multiple endocrine neoplasia types 1 and 2, and isolated phaeochromocytoma are evaluated.
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Ioannis I Androulakis in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
Introduction Neuroendocrine tumours (NETs) are derived from cells that have the unique ability to synthesise, store and secrete a variety of metabolically active substances, peptides and amines, which can cause distinct clinical syndromes. These
University College London Cancer Institute, Neuroendocrine Tumour Unit, 72 Huntley Street, London WC1E 6BT, UK
Search for other papers by A Karpathakis in
Google Scholar
PubMed
Search for other papers by H Dibra in
Google Scholar
PubMed
University College London Cancer Institute, Neuroendocrine Tumour Unit, 72 Huntley Street, London WC1E 6BT, UK
Search for other papers by C Thirlwell in
Google Scholar
PubMed
discovery of mutations in the novel tumour suppressor genes and chromatin remodellers ATRX/DAXX through exome sequencing represent significant progress in our understanding of neuroendocrine tumour (NET) development. NETs are a heterogenous group of
